Atmo Biosciences

Executive Summary

Atmo Biosciences has developed the Atmo Gas Capsule System, a non-invasive diagnostic tool that measures whole gut and regional transit times (stomach, small bowel, colon). This technology addresses motility disorders such as gastroparesis and slow transit constipation, which are underdiagnosed conditions lacking simple, radiation-free measurement options. The capsule measures gas profiles as it traverses the GI tract, enabling precise localization of transit delays. With FDA clearance (or CE mark) already in place, the company is positioned to commercialize a differentiated product in the growing microbiome and GI diagnostics market. The technology offers advantages over traditional methods like scintigraphy (radiation exposure) and wireless motility capsules (limited to transit time only), by providing both regional transit times and gas composition data. Atmo Biosciences targets gastroenterologists and motility clinics, with potential for broad adoption if clinical validation and reimbursement are achieved.

Upcoming Catalysts (preview)

• Q4 2026Commercial launch of Atmo Gas Capsule System in the US70% success
• Q2 2026Key opinion leader (KOL) partnership for clinical trial data publication80% success
• H1 2027Reimbursement code approval from CMS or private payers50% success